Get alerted on the PharmaSources E-Newsletter and Pharma Sources Insight E-Compilation!
Note: You can unsubscribe from the alerts at any time.
Advertising

FDA approves Tafinlar/Mekinist for BRAF V600-mutant melanoma

europeanpharmaceuticalreviewMay 03, 2018

Tag: FDA , melanoma , Novartis

PharmaSources Customer Service